Endocrinology & Oncology & Internal Medicine & Family Medicine
Hypercalcemia
Hypercalcemia is defined as a serum concentration of total calcium above 2.60 mmol/L (10.4 mg/dL), or ionized calcium above 1.30 mmol/L. It represents one of the most frequent electrolyte disorders in clinical practice - encountered in 1 to 2 % of the general outpatient population, and in 0.5 to 3 % of hospitalized patients. Its clinical spectrum is extraordinarily broad: from asymptomatic incidental discovery during a routine blood test, to life-threatening hypercalcemic crisis. Two causes alone account for 90 % of cases: primary hyperparathyroidism (PPH) - the dominant cause in outpatient settings (55-60 % of cases) - and hypercalcemia of malignant origin (20-30 % of cases, dominant in hospital settings). The distinction between these two major etiologies is based primarily on the intact parathyroid hormone (PTH) assay: high or inadequate PTH points to HPP, while low PTH with hypercalcemia suggests a non-parathyroidal cause. The pathophysiology of hypercalcemia necessarily involves one or more of three mechanisms: increased bone resorption (osteoclasts), increased intestinal calcium absorption (calcitriol), or decreased renal calcium excretion. Management is based on etiological treatment, hyperhydration in the acute phase, and specific hypocalcemic treatments (IV bisphosphonates, denosumab, calcitonin) depending on severity and cause.
Pathophysiology, etiologies and clinical presentation
- Normal Calcium Metabolism and Pathophysiological Mechanisms of Hypercalcemia normal calcium homeostasis: total serum calcium: 2.15-2.60 mmol/L → 3 fractions: calcium bound to plasma proteins (mainly albumin): 40-45 % → calcium complexed to anions (citrate + phosphate + bicarbonate): 10-15 % → free ionized calcium (biologically active fraction): 45-50 % → main regulation: PTH (parathormone) + calcitriol (1,25-OH-vitamin D) + FGF-23 + calcitonin + calcium-sensitive receptor (CaSR - Calcium-Sensing Receptor) on parathyroid cells → in case of hypocalcemia → CaSR inactivated → PTH secretion → effects of PTH: osteoclastic bone resorption (activated via RANK-L on osteoblasts) + renal tubular calcium reabsorption (distal tubule) + stimulation of renal 1α-hydroxylase → calcitriol production → increased intestinal calcium absorption → in case of hypercalcemia → CaSR activated → PTH brake → increased calciuria → correction; correction of total calcium for albuminemia: standard formula: corrected calcium (mmol/L) = measured calcium + 0.02 × (40 - albumin g/L) → or in practice: for each g/L of albumin below 40 g/L → add 0.02 mmol/L to measured calcium → example: calcium = 2.45 mmol/L + albumin = 25 g/L → corrected calcium = 2.45 + 0.02 × 15 = 2.75 mmol/L → significant hypercalcemia despite normal total calcium → correction for albumin is essential in malnourished + hepatopathic + nephrotic patients → ionized calcium : reference method if in doubt about interpretation of corrected total calcium → determination on venous or arterial blood + strict pH (pH influences albumin-calcium binding); three main pathophysiological mechanisms: increased osteoclastic bone resorption: elevated PTH (HPP) → activation of RANK-L on osteoblasts → differentiation and activation of osteoclasts → release of calcium + phosphorus + collagen → PTHrP (PTH-related protein) secreted by tumors → mimicry of PTH on the PTH/PTHrP receptor → humoral hypercalcemia of malignant tumors (HHM) → local osteoclastic cytokines (IL-1β + IL-6 + TNF-α + direct RANK-L) : osteolytic bone metastases → local resorption → increased intestinal calcium absorption: calcitriol (1,25-OH-vitamin D) → activation of intestinal VDR receptor → calbindin D9k + TRPV6 transporter → increased calcium absorption in duodenum and jejunum → causes: vitamin D intoxication + sarcoidosis (granulomatous macrophages → unregulated 1α-hydroxylase → autonomous calcitriol production) + lymphomas (extra-renal calcitriol production) → decreased renal calcium excretion: PTH → increased distal tubular calcium reabsorption → thiazides → increased tubular calcium reabsorption → familial hypocalciuric hypercalcemia (FHH - CaSR loss-of-function mutation) → severe CKD (decreased calcium filtration)
- Etiologies—classification and relative frequencies: primary hyperparathyroidism (PPH) - dominant outpatient cause (55-60 %): solitary parathyroid adenoma: 85 % of PPH → autonomous hypersecretion of PTH → hyperplasia of all 4 parathyroid glands: 10-15 % + parathyroid carcinoma: <1 % → variable clinical presentation: asymptomatic (50-80 % of cases in Canada - incidental finding) + recurrent renal lithiasis + osteoporosis + depression/fatigue + NEM1 (Multiple Endocrine Neoplasia type 1 - MEN1 gene - 11q13): HPP + pancreatic neuroendocrine tumor + pituitary adenoma → NEM2A (RET - 10q11.2): HPP + CMT + pheochromocytoma + familial isolated primary hyperparathyroidism (FIHP); hypercalcemia of malignant origin (20-30 % - dominant cause in hospitals): 4 main mechanisms depending on location and tumor type: humoral hypercalcemia of malignant tumors (HHM - 80 % of malignant hypercalcemia): PTHrP (PTH-related protein) secreted by primary tumor → PTH mimicry → bone resorption + renal reabsorption → PTHrP-producing tumors: squamous cell carcinoma (lung + head and neck + esophagus + uterine cervix + skin) + breast carcinoma (some forms) + clear cell renal cell carcinoma + bladder tumors → low PTH + high PTHrP → local osteolysis by metastasis: breast carcinoma (osteolytic - cytokines IL-1β + IL-6 + direct RANK-L) + multiple myeloma (IL-6 + DKK-1 + MIP-1α → potent osteoclastic activation + osteoblastic inhibition → «pure osteolysis») + renal cell carcinoma + lymphoma + bronchial carcinoma → tumoral production of calcitriol : Hodgkin and non-Hodgkin lymphomas (tumor macrophages → 1α-hydroxylase → calcitriol) → low PTH + low PTHrP + high calcitriol → ectopic secretion of PTH by the tumor (very rare <1 %); other causes to be evoked according to context (10-15 %): sarcoidosis and granulomatous diseases (tuberculosis + histoplasmosis + coccidioidomycosis + fungi + berylliosis + Crohn's disease + silicosis): granuloma macrophages → autonomous extra-renal 1α-hydroxylase → elevated calcitriol not regulated by CaSR → hypercalcemia aggravated by sun exposure + vitamin D supplementation → vitamin D intoxication: vitamin D3 overdose + fortified vitamins + excessive fortified milk → very high 25-OH-vitamin D + high calcitriol → massive intestinal absorption → low PTH + very high 25-OHD + thiazides (hydrochlorothiazide + chlorthalidone): mild hypercalcemia by increased tubular calcium reabsorption → also increases renal lithiasis → familial hypocalciuric hypercalcemia (FHH): heterozygous mutation loss of CaSR function → low urinary calcium + normal or slightly elevated PTH → calciuria/creatininuria <0,01 → genetic diagnosis → does not require parathyroid surgery → Foley 2004 - Journal of Bone and Mineral Research + prolonged immobilization (especially in children + adolescents + severe bone Paget) + CKD + lithium (stimulates PTH secretion + shifts CaSR set-point to higher calcium values) + milk-drinking syndrome (milk-alkali syndrome - Pinel 2010 - American Journal of Medicine) : excessive oral calcium + alkalinization → hypercalcemia + metabolic alkalosis + interstitial nephritis → underestimated cause + hyperthyroidism (accelerated bone resorption - severe thyrotoxicosis) + acromegaly (IGF-1 → calcitriol) + adrenal insufficiency (glucocorticoids inhibit calciuria)
- Clinical presentation — «stones, bones, groans, and psychic moans»: classic hypercalcemia mnemonic: stones (kidneys) + bones (bones) + groans (digestive tract) + psychic moans (neuropsychic) + overtones (cardiovascular) → intensity of symptoms correlates with calcium level AND speed of onset; renal manifestations (stones): calcium renal lithiasis (oxalate + phosphate): most frequent complication of chronic HPP → nephro-calcinosis (calcium deposits in renal parenchyma) → chronic renal failure → polyuria-polydipsia (nephrogenic diabetes insipidus): PTH + hypercalcemia → inactivation of AQP2 (aquaporin 2) in the collecting tubule → resistance to ADH → osmotic diuresis + hypercalciuria → dehydration → vicious circle (dehydration → worsening of hypercalcemia); bone manifestations (bones): severe and prolonged HPP → cystic fibrous osteitis (osteitis fibrosa cystica - Von Recklinghausen 1891): today exceptional in high-income countries (early detection) → bone pain + pathological fractures + cystic lesions («brown tumors» - osteoclastomas) + skeletal deformities → osteoporosis (chronic resorption) → reduced bone mineral density (BMD) at distal radius (cortical) → cortical predominance of HPP resorption → relate to T-score; digestive manifestations (groans): nausea + vomiting + anorexia + constipation (hypercalcemia → hypotonia of intestinal smooth muscle + dehydration) → abdominal pain + acute pancreatitis: calcium → activation of pancreatic enzymes (trypsinogen → trypsin) → pancreatic lesions → vesicular lithiasis (calcifications); neuropsychic manifestations (psychic moans): mild (2.6-3.0 mmol/L): fatigue + irritability + depression + difficulty concentrating + memory disorders + moderate (3.0-3.5 mmol/L): confusion + lethargy + muscle weakness (muscle hypotonia - hypercalcemia → partial inactivation of voltage-dependent sodium channels → slowing of nerve conduction) + severe (>3.5 mmol/L): stupor + coma + possible cardiorespiratory arrest; cardiovascular manifestations (overtones): shortening of QT interval → shortening of ventricular repolarization → potentially severe arrhythmias → atrioventricular block → bradycardia → ventricular fibrillation if >3.75 mmol/L → arterial hypertension (contraction of vascular smooth muscle cells) → vascular and valvular calcifications (chronic hypercalcemia)
Biological diagnostics, imaging, and management
| Aspect / intervention | Data, criteria, and terms | Key studies and recommendations |
|---|---|---|
| Etiological diagnostic assessment — algorithm and interpretation Intact PTH — PTHrP — 25-OHD — calcitriol — calciuria — Bence-Jones protein — parathyroid scan |
Diagnostic algorithm based on intact PTH (mandatory first step): Intact PTH elevated or inadequately normal (>25 pg/mL with hypercalcemia): primary hyperparathyroidism (HPP) in 95 % of cases → confirm with 2 spaced corrected calcium + PTH assays → exclude FHH: 24h calciuria/creatininuria → calciuria/creatininuria ratio 0.02 → HPP confirmed → exclude drugs: lithium → withdrawal × 3 months if possible before confirming HPP → localization imaging (DOES NOT change diagnosis - confirms topography): cervical ultrasound + MIBI (sestamibi Tc99m) parathyroid scintigraphy + 4D CT (4-phase CT) + ultrasound-guided if necessary → low PTH (150 nmol/L) → vitamin D intoxication → calcitriol (1,25-OH-vitamin D): high with low PTH + low PTHrP + normal or low 25-OHD → lymphoma + sarcoidosis + other granulomatosis → serialized ACE (angiotensin-converting enzyme) → gallium scintigraphy or PET-CT → broncho-alveolar lavage if sarcoidosis → CBC + serum protein electrophoresis + immunofixation + kappa/lambda light chains + Bence-Jones proteinuria + myelogram → multiple myeloma → bilirubin + alkaline phosphatases + LDH → granulomatous hepatitis + Hodgkin's disease ; complete first-line laboratory work-up in cases of confirmed hypercalcemia: total calcium corrected for albumin + ionized calcium (if in doubt) + albumin + phosphorus (low in HPP - PTH → phosphaturia; high in CKD + D intoxication) + creatinine + GFR + intact PTH (immunoradiometric or electrochemiluminescence - precise, standardized assay) + magnesium (hypoMg → PTH resistance → pseudo-HPP) + bone alkaline phosphatases (bone ALPs): elevated if increased bone turnover (active HPP + osteolytic metastases) + 24h calciuria + creatininuria → Ca/Creat ratio + CBC + ESR + CRP (infection + granulomatosis + myeloma) + TSH (hyperthyroidism) + morning cortisol if adrenal insufficiency suspected + 25-OHD + calcitriol according to context + PTHrP according to context (if PTH low + no obvious cause) + EPP + immunofixation + serum free light chains (myeloma) + targeted bone X-rays if pain (lytic lesions) + bone scintigraphy (metastases) + CT TAP + thyroid work-up + PSA if male ≥50 years ; classification of hypercalcemia severity according to corrected calcium: mild: 2.60-3.00 mmol/L → often asymptomatic → etiological investigation + follow-up → moderate: 3.00-3.50 mmol/L → variable symptoms → treatment according to etiological context → severe: >3.50 mmol/L → almost constant significant symptoms → active treatment required → hypercalcemic crisis: >3.75 mmol/L + severe symptoms (confusion + stupor + arrhythmia) → medical emergency → hospitalization + immediate IV treatment | Differential diagnosis HPP vs malignant hypercalcemia - key points: HPP: slow onset (months to years) + frequently asymptomatic + elevated PTH + hypophosphatemia + normal or elevated calciuria + patient often ambulatory in good general health → malignant hypercalcemia: rapid onset (days to weeks) + marked symptoms + low PTH + PTHrP often elevated + neoplastic context + altered general condition + Bilezikian 2022 - Journal of Clinical Endocrinology and Metabolism : international guidelines HPP → diagnosis + follow-up + surgical indications → corrected calcium >2.85 mmol/L (0.25 mmol/L above the upper limit of normal) = absolute surgical criterion in asymptomatic HPP + Eastell 2014 - Journal of Clinical Endocrinology and Metabolism: 4th International Workshop on Asymptomatic Primary Hyperparathyroidism → standardized surgical indications; MIBI parathyroid scintigraphy: sensitivity 70-80 % for solitary adenomas + 4D CT: sensitivity 80-85 % + cervical ultrasound: sensitivity 60-75 % + operator-dependent → combination MIBI + 4D CT: sensitivity 90-95 % → localization workup does not confirm the diagnosis of HPP - it localizes the adenoma to guide the surgeon |
| Management of Acute Hypercalcemia and Hypercalcemic Crisis Hyperhydration — furosemide — IV bisphosphonates — denosumab — calcitonin — hemodialysis — glucocorticoids |
Principles of treatment for symptomatic or severe hypercalcemia (calcium >3.0-3.25 mmol/L): step 1 - intravenous hyperhydration (always the first measure): saline (NaCl 0.9 %) IV: 200-300 mL/h → goal: diuresis ≥100-150 mL/h → mechanism: volume expansion → increase in GFR → increase in calciuria → dilution of serum calcium → reduction in proximal tubular calcium reabsorption → quantity: 3-6 L/24h depending on tolerance (cardiac + renal + pulmonary edema monitoring) → correct concomitant hypokalemia (forced diuresis → kaliuresis) → monitor ionogram + diuresis every 4-6h; step 2 - intravenous bisphosphonates (most effective background therapy - 24-72h delay): zoledronate (zoledronic acid - Zometa) 4 mg IV in 15 min: gold-standard treatment for severe hypercalcemia in cancer → mechanism: inhibition of farnesyl-pyrophosphate synthase → osteoclast apoptosis → arrest of bone resorption → onset of action: 24-72h → maximum effect on D3-J7 → duration of effect: 3-4 weeks (sometimes longer) → Major 2001 - Journal of Clinical Oncology: zoledronate vs pamidronate → calcium normalization in 88 % vs 70 % + faster response time → pamidronate (Aredia) 60-90 mg IV in 2-4h: alternative if zoledronate unavailable or moderate renal impairment → calcium normalization in 70-100 % depending on dose → bisphosphonates contraindication: GFR <30 mL/min for zoledronate (adapt dose or avoid) → GFR <30 mL/min for pamidronate (use with caution) → adverse effects: flu-like syndrome (fever + myalgias + arthralgias) 24-48h after infusion + osteonecrosis of the jaw (prolonged use) + atypical fractures of the femur (prolonged use) + nephrotoxicity (zoledronate to be infused in ≥15 min, never bolus); step 3 - calcitonin (Miacalcin / salmon calcitonin): 4-8 IU/kg SC or IM every 6-12h → mechanism: direct inhibition of osteoclasts (rapid) + increase in renal calciuria → advantage: rapid onset of action (4-6h) → shorter delay than bisphosphonates → disadvantage: modest effect (reduction of 0.3-0.5 mmol/L) + tachyphylaxis in 24-48h (loss of efficacy through down-regulation of receptors) → role: immediate relay treatment while awaiting effect of bisphosphonates → Wisneski 1990 - Calcified Tissue International: calcitonin + pamidronate → temporary synergy → do not use alone as prolonged treatment; step 4 - denosumab (Xgeva / Prolia): anti-human RANK-L monoclonal antibody → potent, prolonged inhibition of osteoclast differentiation and activity → 120 mg SC → main indication: hypercalcemia refractory to bisphosphonates (cancer + myeloma) + renal failure (GFR <30 mL/min) where bisphosphonates are contraindicated → Hu 2014 - Journal of the National Cancer Institute: denosumab → calcium normalization in 64 % of bisphosphonate-refractory cases → onset of action: 2-4 days → duration of effect: 4-8 weeks → adverse effects: severe hypocalcemia + hypophosphatemia after treatment → monitor calcium + phosphorus + magnesium → calcium + vitamin D supplementation imperative unless hypercalcemia → osteonecrosis of the jaw (prolonged use); step 5 - glucocorticoids: specific indication: hypercalcemia on sarcoidosis + granulomatoses + lymphomas + vitamin D intoxication + mechanism: inhibition of extra-renal 1α-hydroxylase + reduced calcitriol production + reduced intestinal calcium absorption → prednisone 20-40 mg/d → efficacy in 48-72h → avoid in PPH and humoral hypercalcemia of malignancies (ineffective) → Adams 1999 - Seminars in Nephrology: glucocorticoids + sarcoidosis → calcium normalization in 80-90 % of cases; step 6 - hemodialysis or hemofiltration: rare but vital indication: severe hypercalcemia + severe CKD or anuric renal failure → inability to hyperhydrate + inability to use bisphosphonates → calcium-free or low-calcium dialysate → direct calcium elimination → rapid efficacy (single session → significant reduction) → reserved for refractory cases + patients with end-stage renal failure + furosemide: controversial use and abandoned routinely: initially used to force calciuria (1 mg/kg IV) → but: worsens dehydration if used without sufficient prior hyperhydration → risk of hypokalemia + hypomagnesemia + GFR collapse → currently reserved for documented hydrosodium overload (heart failure + overload) → NOT routinely used in the treatment of hypercalcemia (Ziegler 2010 - Endocrinology and Metabolism Clinics) | Comparative efficacy of calcium-lowering treatments: Major 2001 - Journal of Clinical Oncology (RCT n=287): zoledronate 4 mg vs pamidronate 90 mg → calcium normalization: 88 % vs 70 % (p=0.002) → median time to normalization: 4 vs 7 days → median duration of response: 32 vs 18 days → zoledronate = current standard for malignant hypercalcemia + Hu 2014 - Journal of the National Cancer Institute: denosumab + bisphosphonate-refractory malignant hypercalcemia → response in 64 % + Cardella 2015 - Clinical Journal of the American Society of Nephrology: denosumab + severe CKD → comparable efficacy without nephrotoxicity → recommended as 1st-line therapy if GFR <30 mL/min + Avenell 2019 - Cochrane Review: bisphosphonates + asymptomatic HPP → modest calcium reduction + improved BMD → alternative to surgery in non-operable patients; action times to remember in practice: calcitonin: 4-6h (but tachyphylaxis in 48h) → hyperhydration: 4-12h → IV bisphosphonates: 24-72h (maximum effect D3-J7) → denosumab: 2-4 days → glucocorticoids: 24-72h (if sarcoidosis + lymphoma + vit D) → parathyroid surgery: definitive cure in HPP |
| Primary Hyperparathyroidism (PHPT) - Specific Management and Surgery Parathyroidectomy — surgical indications — cinacalcet — monitoring — osteoporosis — kidney stones — MEN |
Operative indications in asymptomatic HPP - 4th International Workshop 2014 (Eastell / Bilezikian) and 2022 update: parathyroid surgery recommended if any of the following criteria are present: corrected calcium > upper limit of normal + 0.25 mmol/L (in practice >2.85 mmol/L according to laboratories) + GFR 10 mmol/d (hyperexcretion) OR renal lithiasis or nephro-calcinosis documented on imaging + age <50 years (long life expectancy → cumulative risk of complications) + monitoring impossible or not desired by patient ; symptomatic HPP (recurrent renal lithiasis + fractures + severe osteoporosis + pancreatitis): surgical indication in all cases; surgical technique: MIBI-guided minimally invasive parathyroidectomy (MIGP): resection of localized solitary adenoma + intraoperative confirmation by rapid PTH (50 % decay in 10 min confirms resection of all hyperfecting tissue) → Bilezikian 1995 - Journal of Bone and Mineral Research: cure in 95-98 % of cases + exploration of all 4 glands (open bilateral exploration): if non-localized adenoma or hyperplasia or suspected NEM1 + cure : calcium normalization in 24-72h + intraoperative PTH normalization → complications: postoperative hypocalcemia (hungry bone syndrome: increased ossification post-PTH → rapid calcium uptake by bone → transient hypocalcemia sometimes prolonged) → calcium supplementation PO + calcitriol + recurrent laryngeal nerve involvement (hoarse voice) → <1 % experienced centers; postoperative follow-up of non-operated HPP or awaiting surgery: biannual monitoring: calcium + PTH + creatinine + GFR + urinary calcium + annual: BMD (DXA bone densitometry) + renal ultrasound (lithiasis) → patient not operable or refusing surgery → medical treatment: cinacalcet (calcimimetic - Sensipar 30-90 mg/d): activates CaSR → slows PTH → normalizes calcium in 75-85 % of cases + but: does not reduce PTH like surgery → no improvement in BMD (Peacock 2009 - Journal of Clinical Endocrinology and Metabolism) → bisphosphonates (alendronate): improve BMD but do not lower serum calcium + treatment of associated lithiasis: hyperhydration + tamsulosin + urological surgery as indicated; HPP in NEM1 context: mandatory bilateral exploration of all 4 glands (frequent multigland hyperplasia) + subtotal (3.5 glands) or total resection with autotransplantation → lifelong monitoring (frequent recurrence) + family screening (MEN1 gene - autosomal dominant) | Benefits of parathyroidectomy in HPP - key data: Rao 2004 - Surgery: parathyroidectomy in asymptomatic HPP → improved quality of life + reduced anxiety + partial regression of bone lesions → Bollerslev 2015 - European Journal of Endocrinology: post-parathyroidectomy healing → 5-10 % recovery of lumbar and femoral BMD at 1 year + reduced risk of vertebral fractures + Vestergaard 2005 - World Journal of Surgery: parathyroidectomy → 50 % reduction in risk of recurrent renal lithiasis at 5 years + Silverberg 2015 - Journal of Bone and Mineral Research: 15-year follow-up of unoperated PPH → 30 % of patients develop a surgical criterion within 15 years → 70 % remain stable → surveillance is a valid option in patients without a criterion but implies strict regular follow-up; surveillance modalities for unoperated PPH in Canada: Canadian Endocrine Update 2023 + CPSA + SOGC recommendations: calcium + PTH + creatinine + GFR → every 6 months for 2 years → then annually if stable → BMD (hip + spine + distal radius) → annually × 2 years → then every 2 years if stable → renal ultrasound + low-dose CT if symptoms → annually |
| Malignant hypercalcemia - oncological specificities PTHrP — myeloma — bone metastases — zoledronic acid — denosumab — palliative care — prognosis |
Malignant hypercalcemia - epidemiology and prognosis: frequency: 20-30 % of cancer patients will develop hypercalcemia during the course of the disease → more frequent complication in certain cancers: squamous cell carcinoma of the lung (35 % of malignant hypercalcemia) + breast carcinoma + multiple myeloma + Hodgkin's lymphoma + renal cell carcinoma + head and neck carcinoma + dismal prognosis: malignant hypercalcemia is a sign of advanced disease → median survival after first episode of malignant hypercalcemia: 30-60 days according to historical series + with effective oncological treatments: prolonged survival possible → treated malignant hypercalcemia may correct if tumor responds to antineoplastic therapy; mechanisms according to cancer type (Mundy 1997 - New England Journal of Medicine): HHM mechanism (PTHrP): squamous cell carcinoma of the lung + breast carcinoma + renal carcinoma + head and neck carcinoma + bladder carcinoma → direct osteolysis + local cytokines : multiple myeloma (IL-6 + MIP-1α + direct RANK-L + DKK-1 - inhibition of osteogenesis → disrupted bone coupling → summary: myeloma → high resorption + low formation → pure lytic lesions without sclerosis) + breast carcinoma with bone metastases + renal carcinoma + calcitriol production: Hodgkin's lymphoma + non-Hodgkin's lymphomas (T-cell) → tumor macrophages + 1α-hydroxylase → high calcitriol → low PTH + low PTHrP + ectopic PTH secretion (very rare): neuroendocrine carcinomas + rare primary lung tumors; treatment of malignant hypercalcemia - standard protocol: emergency if calcium >3.0-3.25 mmol/L or symptoms: 1. Hyperhydration NaCl 0.9 % 200-300 mL/h + cardiac monitoring 2. Zoledronate 4 mg IV over 15 min (GFR >30 mL/min) OR pamidronate 90 mg IV if GFR 30-60 mL/min 3. Calcitonin 4-8 IU/kg SC every 6-8h × 24-48h (rapid onset of action while waiting for bisphosphonate) 4. If refractory or GFR <30 mL/min: denosumab 120 mg SC → monitoring: calcium + electrolytes + creatinine + diuresis every 4-6h → target: calcium <2.9 mmol/L → then etiological treatment of underlying neoplasia (chemotherapy + immunotherapy + bone radiotherapy + surgery) as the best guarantee against recurrence of hypercalcemia; prophylactic treatment of bone complications in cancers with bone metastases or myeloma (CTIOM - Canadian Treatment Information for Oncology Management): zoledronate 4 mg IV q3-4 weeks OR denosumab 120 mg SC q4 weeks → reduction in bone events (fractures + spinal cord compression + hypercalcemia + pain requiring radiotherapy) → Morgan 2011 - Lancet Oncology (meta-analysis): zoledronate in breast cancer with metastases → reduction in bone events by 32 % → denosumab superior to zoledronate for reduction in bone events in certain cancers (Stopeck 2010 - Journal of Clinical Oncology) but not for overall survival; palliative setting and comfort goals: if malignant hypercalcemia in an end-of-life context → goals focused on comfort → oral hyperhydration if possible → bisphosphonate if symptomatic benefit expected → calcitonin SC if very symptomatic hypercalcemia → do not systematize aggressive treatments if prognosis <1-2 weeks → multidisciplinary discussion + palliative care team | Comparative efficacy data in malignant hypercalcemia: Major 2001 - Journal of Clinical Oncology: n=287 + zoledronate 4 mg → response rate 88 % + median time to normalization 4 days + median duration of response 32 days → superior to pamidronate on all criteria → Hu 2014 - Journal of the National Cancer Institute: denosumab in hypercalcemia refractory to bisphosphonates → response in 64 % of cases → median duration of response: 26 days → Stopeck 2010 - Journal of Clinical Oncology (RANKL trial): denosumab vs zoledronate in breast cancer with bone metastases → median time to 1st bone event: 26.4 vs 19.4 months → denosumab superior → but: no difference in overall survival + higher risk of hypocalcemia with denosumab → calcium + vitamin D supplementation mandatory unless hypercalcemia; role of bone radiotherapy: painful bone metastases + risk of fracture + spinal cord compression → palliative radiotherapy + local reduction of osteoclastic activity → local reduction of tumor PTHrP → contribution to control of local hypercalcemia but insufficient alone if systemic hypercalcemia |
ℹ️
Always correct calcium for albuminemia before interpreting a result: In a malnourished, hypoalbuminemic, or critically ill patient, the measured total calcium underestimates the actual active calcium. The correction formula (+0.02 mmol/L per g/L of albumin below 40 g/L) is essential. If in doubt, ionized calcium measured on venous (or arterial) blood remains the absolute reference. Intact PTH measured simultaneously with corrected calcium is key to etiological diagnosis and guides the entire approach.
Situations Requiring a 911 Call or Urgent Emergency Room Visit
Corrected calcium > 3.50 mmol/L (hypercalcemic crisis) with confusion, lethargy, stupor, repeated vomiting, or anuria → metabolic emergency → call 911 → emergency hospitalization → IV hyperhydration + IV bisphosphonate + SC calcitonin + ECG (risk of severe arrhythmia + QT shortening + AV block) → ICU monitoring if calcium >3.75 mmol/L.
Moderate to severe hypercalcemia (calcium >3.0 mmol/L) in a patient with known active cancer Malignant hypercalcemia → Oncologic emergencies → Zoledronic acid + hyperhydration + calcitonin → Reassessment of antineoplastic treatment → Discussion with the treating oncologist.
Unexplained cardiac arrhythmia (bradycardia + AV block + short QT) + hypercalcemia discovered on ECG or during workup → risk of ventricular fibrillation if calcium > 3.75 mmol/L → cardiac emergency → 12-lead ECG + continuous monitoring + emergency hypocalcemic treatment.
Acute low back pain + nausea + high calcium in a patient with known hyperparathyroidism or massive calcium/vitamin D supplements → Obstructive renal lithiasis + simultaneous hypercalcemia → emergencies → renal ultrasound + renal workup + correction of hypercalcemia + urological management according to the presentation.
Consult at Clinique Omicron
Clinique Omicron physicians assess mild to moderate hypercalcemia discovered during outpatient visits, prescribe and interpret the complete etiological workup (PTH, corrected calcium, 25-OHD, calciuria), refer to an endocrinologist or urologist depending on the etiology, and provide follow-up for patients with asymptomatic primary hyperparathyroidism. Consultations are available at several service points across Quebec and via telemedicine. To book an appointment, visit cliniqueomicron.ca.
The content of this page is provided for informational purposes only and does not substitute for medical advice. Severe hypercalcemia (calcium >3.50 mmol/L) or hypercalcemia associated with severe symptoms is a medical emergency requiring immediate hospital evaluation.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.